Insider buying · SEC Form 4

WGS insider buying

Open-market purchases of GeneDx Holdings Corp. (WGS) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

5insider buys on record
$125Mbought in total
2different insiders
0by CEOs, CFOs and other chiefs
May 27, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
May 27, 2026Eli CasdinDirector, 10% Owner$21.5M500,000$42.92AddedMay 22, 2026
Casdin Partners Master Fund bought 175K shares (May 18, $42.55 avg), 185K (May 19, $42.60 avg), 140K (May 20, ~$43.80 avg); blended avg $42.92; now $49.44 (+15.2%); cluster buy alongside director Meister (+$13.8M same window)
May 27, 2026Keith A. MeisterDirector$13.8M351,273$39.20AddedMay 21, 2026
Bought 351,273 shares over 3 trading days (May 18–20); weighted avg ~$39.20/share; now $49.44 (+26.1%); simultaneous with Casdin's $21.5M buy — rare dual-director cluster signal in healthcare genomics
May 26, 2026Eli CasdinDirector (via Casdin Partners Master Fund)$21.5M500,000$42.92AddedMay 22, 2026
Form 4 ↗
Bought 175K shares at $42.55 (May 18), 185K at $42.59 (May 19), 140K at $43.81 (May 20); weighted avg $42.92; now $47.31 (+10.2%). Post-Q1 2026 earnings conviction buy. Three-day accumulation by fund controlled by director.
May 22, 2026Eli CasdinDirector, 10% Owner$21.5M500,000$42.92AddedMay 21, 2026
Form 4 ↗
Casdin Partners Master Fund bought 500K shares across May 18–20 at wtd-avg ~$42.92 (range $42.46–$43.81). Post-buy spot $47.33 (+10.3%). Director and 10% owner of the genomic-testing platform; fund now holds 3.51M shares. High-conviction buy cluster coinciding with strong Q1 earnings momentum.
May 12, 2026Keith A. MeisterDirector & 10% Owner (via Corvex Management LP)$46.8M1,205,147$38.83AddedMay 12, 2026
Form 4 ↗
Corvex Management LP funds bought 1,205,147 Class A shares over May 7–11 at range $35.46–$41.15; weighted avg ~$38.84/share. Spot $39.61 (+2.0% vs avg buy price). Post-transaction Corvex directly holds 4,433,297 shares. GeneDx trimmed 2026 revenue guidance in April following Q1 loss widening; investor alert investigation announced May 6. Largest outside shareholder accumulating aggressively on the dip.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.